CTOs on the Move

M3

www.m3as.com

 
The best back-office hosted software solution provider for the Hospitality Industry. We provide accounting, business intelligence, and payroll solutions across all brands and independent hotels in the U.S. and Canada. Our enterprise level solution allows franchisees access to their financial and operating information in real-time with user friendly reports. Our clients are able to reduce overhead and labor by leveraging our solutions to remain competitive in the industry.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.m3as.com
  • 1715 North Brown Road Building. A
    Lawrenceville, GA USA 30043
  • Phone: 770.297.1925

Executives

Name Title Contact Details
Michael Mitchell
 Vice President, IT and Security Profile

Similar Companies

PC Clean Machine

PC Clean Machine is a Fort Washington, PA-based company in the Software and Internet sector.

Blue Equinox

Blue Equinox | IT Consulting | Managed IT Services | Nashville IT Made Simple. Seasoned IT expert and CIO-level support for your small and mid-sized business needs. Nashville-based with national partners. IT Support Nashville, Scalable IT, Support IT, ...

Igicom

Igicom is a New York, NY-based company in the Software and Internet sector.

HelloTech

HelloTech is changing the way consumers purchase and get support for new technology. Utilizing a background-checked, vetted on-demand workforce, HelloTech provides in home support and consultation for consumers looking to manage and upgrade the technology within their home.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.